Increased transmucosal uptake of E. coli K12 in collagenous colitis persists after budesonide treatment

American Journal of Gastroenterology

Volumn 104, Issue 3, 2009, Pages 679-685

  Münch, Andreas ^a,c   Söderholm, Johan D ^a   Öst, Åke ^b   Ström, Magnus ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

^b Medilab   (Sweden)

^c LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BUDESONIDE;

ADULT; AGED; ARTICLE; CELL MEMBRANE PERMEABILITY; CLINICAL ARTICLE; COLLAGENOUS COLITIS; ENDOSCOPIC BIOPSY; ESCHERICHIA COLI K 12; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PRIORITY JOURNAL; REMISSION; SIGMOID;

AGED; ANTI-INFLAMMATORY AGENTS; BUDESONIDE; COLITIS, COLLAGENOUS; ELECTRIC IMPEDANCE; ESCHERICHIA COLI K12; FEMALE; HUMANS; INTESTINAL MUCOSA; MALE; RECURRENCE;

EID: 62049085890     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2008.95     Document Type: Article

References (56)

1. Olesen M, Eriksson S, Bohr J et al. Microscopic colitis: a common diarrhoeal disease. An epidemiologic study in Örebro, Sweden 1993-1998. Gut 2004;53:346-05.
2. Wickbom A, Nylin N, Eriksson S et al. Collagenous colitis and lymphocytic colitis in Örebro, Sweden 1999-2004; a Continuous Epidemiologic Study. Gut 55 (Suppl): abstract Mon-G-156.
3. Pardi DS, Loftus EV, Smyrk TC et al. The epidemiology of microscopic colitis: a population based study in Olmsted County, Minnesota. Gut 2007;56:504-8.
4. Warren BF, Edwards CM, Travis SP. Microscopic colitis classification and terminology. Histopathology 2002;40:374-6.
5. Bohr J, Tysk C, Yang P et al. Autoantibodies and immunoglobulins in collagenous colitis. Am J Gastroenterol 1992;87:780-3.
6. Freeman HJ. Perinuclear autoneutrophil cytoplasmic antibodies in collagenous or lymphocitic colitis with or without celiac disease. Can J Gastroenterol 1997;11:417-20.
7. Ung KA, Gillberg R, Kilander A et al. Role of bile acids and bile acids binding agents in patients with collagenous colitis. Gut 2000;46:170-5.
8. Bohr J, Nordfelth R, Jörnerot G et al. Yersinia species in collagenous colitis: a serologic study. Scand J Gastroenterol 2002;37:711-7.
9. Beaugerie L, Pardi DS. Review article: drug-induced microscopic |colitis - proposal for a scoring system and review of the literature. Aliment Pharmacol Ther 2005;22:277-84.
10. Nyhlin N, Bohr J, Eriksson S et al. Systemic review: microscopic colitis. Aliment Pharmacol Ther 2006;23:1525-34.
11. Järnerot G, Tysk C, Bohr J et al. Collagenous colitis and fecal stream diversion. Gastroenterology 1995;109:449-55.
12. Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology. Lancet 2007;369:1627-04.
13. Irvine EJ, Marschall JK. Increased intestinal permeability precedes the onset of Crohn's disease in a subject with familial risk. Gastroenterology 2000;119:1740-4.
14. Buhner S, Buning C, Genschel J et al. Genetic basis for increased intestinal permeability in families with Crohn's disease: role of CARD 15 3020insC mutation. Gut 2006;5:342-7.
15. Söderholm JD, Olaison G, Lindberg E et al. Different intestinal permeability patterns in relatives and spouses of patients with Crohn's disease: an inherited defect in mucosal defence? Gut 1999;44:96-100.
16. Söderholm DJ, Peterson KH, Olaison G et al. Epithelial Permeability to proteins in the noninflamed ileum of Crohn's disease? Gastroenterology 1999;17:65-7.
17. Söderholm JD, Olaison G, Peterson KH et al. Augmented increase in tight junction permeability by luminal stimuli in the non-inflamed ileum of Crohn's disease. Gut 2002;50:307-13.
18. Münch A, Söderholm JD, Wallon C et al. Dynamics of mucosal permeability and inflammation in collagenous colitis before, during, and after loop ileostomy. Gut 2005;54:1126-8.
19. Bürgel N, Bojarski C, Mankertz J et al. Mechanisms of diarrhea in collagenous colitis. Gastroenterology 2002;123:433-43.
20. Baert F, Schmit A, d'Haens D et al. Budesonide in collagenous colitis: a double-blind, placebo-controlled trial with histologic follow-up. Gastroenterology 2002;122:22-5.
21. Bonderup OK, Hansen JB, Birket-Smith L et al. Budesonide treatment of collagenous colitis: a randomised, double-blind, placebo controlled trial with morphometric analysis. Gut 2003;53:248-51.
22. Miehlke S, Heymer P, Bethke B et al. Budesonide treatment for collagenous colitis: a randomized, double-blind, placebo-controlled, multicenter trial. Gastroenterology 2004;126 (Supp 2): A465.
23. Munck LK, Kjelden J, Philisen E et al. Incomplete remission with short-term prednisolone treatment in collagenous colitis: a randomized study. Scand J Gastroenterol 2003;38:606-10.
24. Fine K, Ogunji F, Lee E et al. Randomized, double-blind, placebo controlled trial of bismuth subsalicylate for microscolic colitis. Gastroenterology 1999;116:A880.
25. Madisch A, Miehlke S, Eichele E et al. Boswellia serrata extract for the treatment of collagenous colitis: a randomized, double-blind, placebo-controlled, multicenter trial. Gastroenterology 2005;128 (4 supp 2): A581.
26. Wildt S, Munck LK, Vinter-Jensen L et al. Probiotic treatment of collagenous colitis: a randomized, double-blind, placebo-controlled trail with Lactobacillus acidophilus and Bifidobacterium animalis subsp. Lactis. Inflamm Bowel Dis 2006;12:395-401.
27. Chande N, McDonald JWD, Mac Donald JK. Interventions for treating collagenous colits. Cochrane Database of Systematic Reviews 2008, Issue 4.
28. Miehlke S, Madisch A, Voss C et al. Long term follow-up of collagenous colits after induction of clinical remission with budesonide. Aliment Pharmacol Ther 2005;22:1115-9.
29. Clayburgh DR, Shen L, Turner JR. A porous defense: the leaky epithelial barrier in intestinal disease. Lab Invest 2004;84:282-91.
30. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007;448:427-34.
31. Sartor RB. Microbial influences in inflammatory bowel diseases. Gastroenterology 2008;134:577-94.
32. Wallon C, Braaf Y, Wolving M et al. Endoscopic biopsies in Ussing chamber evaluated for studies of macromolecular permeability in the human colon. Scand J Gastroenterol 2005;40:586-95.
33. Wan CP, Park CS, Lau BH. A rapid and simple microfluorometric phagocytosis assay. J Immunol Methods 1993;162:1-7.
34. Keita AV, Gullberg E, Ericson AC et al. Characterization of antigen and bacterial transport in the follicle-associated epithelium of human ileum. Lab Invest 2006;86:504-61.
35. Bogomoletz WV. Collagenous, microscopic and lymphocytic colitis. An evolving concept. Virchows Archiv 1994;424:573-9.
36. Geboes K, Ridell R, Öst Å et al. A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. Gut 2000;47:404-9.
37. Bonderup OK, Hansen JB, Teglbjaerg PS et al. Long-term budesonide treatment of collagenous colitis - a randomized, double-blind, placebo-controlled trial. Gut 2007;56 (Supp 3): A53.
38. Rhodes JM. The role of Escherichia coli in inflammatory bowel disease. Gut 2007;56:610-2.
39. Darfeuille-Michaud A, Boudeau J, Bulois P et al. High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's disease. Gastroenterology 2004;127:412-21.
40. Alpern J, Sasaki M, Sitaraman S et al. Invasive E. coli strains are increased in Crohns's disease. Gastroenterology 2006;130:A-362.
41. Kotlowski R, Bernstein CN, Sepehri S et al. High prevalence of Escherichia coli belonging to the B2 and D phylogenetic groups in inflammatory bowel disease. Gut 2007;56:669-57.
42. Subramanian S, Campbell BJ, Rhodes JM. Bacteria in the pathogenesis of inflammatory bowel disease. Curr Opin Infect Dis 2006;19:475-84.
43. Williams-Smith H. Is it safe to use Escherichia coli in recombinant DNA experiments?. J Infect dis 1978;137:655-60.
44. Curtiss R. Biological containment and cloning vector transmissibility. J Infect Dis 1978;137:668-75.
45. Clark E, Hoare C, Tanianis-Hughes J et al. Interferon γ induces translocation of commensal Escherichia coli across Gut epithelial cells via a lipid raft-mediated process. Gastroenterology 2005;128:1258-67.
46. Schmitz H, Barmeyer C, Fromm M et al. Altered tight junction structure contributes to the impaired epithelial barrier function in ulcerative colitis. Gastroenterology 1999;16:301-9.
47. Sandle GI, Higs N, Crowe P et al. Cellular basis for defective electrolyte transport in inflamed human colon. Gastroenterology 1990;99:97-105.
48. +-ATPase. J Clin Invest 2002;110:1739-47.
49. Tagkalidis P, Gibson PR, Bhathal PS. Microscopic colitis demonstrates a T helper cell type 1 mucosal cytokine profile. JClin Pathol 2007;60:382-7.
50. Zeissig S, Fromm A, Mankertz J et al. Butyrate induces intestinal sodium absorption via Sp-mediated transcriptional up-regulation of epithelial sodium channels. Gastroenterology 2007;132:236-84.
51. Hirata F, Stracke ML, Schiffmann E. Regulation of prostaglandin formation by glucocorticoids and their second messenger, lipocortins. J Steroid Biochem 1987;27:1053-6.
52. Funder JW. Mineralocorticoids, glucocorticoids, receptors and response elements. Science 1993;259:1132-3.
53. Sellin JH, DeSoignie RC. Steroids alter ion transport and absorptive capacity in the proximal and distal colon. Am J Physiol 1985;249:113-9.
54. Zareie M, Brattsand R, Sherman PM et al. Improved effects of novel glucocorticosteroids on immune-induced epithelial pathophysiology. J Pharmacol Exp Ther 1999;289:1245-9.
55. Bajor A, Kilander A, Galman C et al. Budesonide treatment is associated with increased bile acid absorption in collagenous colitis. Aliment Pharmacol Ther 2006;24:164 3-9.
56. Münch A, Ström M, Söderholm DJ. Dihydroxy bile acids increase mucosal permeability and bacterial uptake in human colon biopsies. Scand J Gastroenterol 2007;42:1-8.